One gene to rule them all…and in the darkness bind them

Pharmaceutical inhibition of the Human Epidermal growth factor Receptor 2 ( oncogene has dramatically improved outcomes in -amplified breast cancers. However, monotherapy HER2 inhibitors are not effective. We have recently reported that a co-amplified microRNA within the amplicon, leads to activatio...

Full description

Saved in:
Bibliographic Details
Published inMolecular & cellular oncology Vol. 5; no. 4; p. e1465881
Main Authors Floros, Konstantinos V, Faber, Anthony C
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 04.07.2018
Taylor & Francis Group
Subjects
apoptosis
Author's Views
breast cancer
mcl1 inhibitor
mir-4728
noxa
apoptosis
Breast cancer
MCL1 inhibitor
NOXA
miR-4728
Online AccessGet full text

Cover

More Information
Summary:Pharmaceutical inhibition of the Human Epidermal growth factor Receptor 2 ( oncogene has dramatically improved outcomes in -amplified breast cancers. However, monotherapy HER2 inhibitors are not effective. We have recently reported that a co-amplified microRNA within the amplicon, leads to activation of the oncogene Myeloid Cell Leukemia-1 ( ), tempering cell death responses to HER2 inhibitors. Importantly, HER2 inhibitors are sensitized to cell death by the addition of pharmacological MCL-1 inhibitors, which are entering clinical trials.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Present Address: Neurosurgery Unit for Pituitary and Inheritable Diseases, Surgery Neurology Branch (SNB), National Institute of Neurological Diseases and Stroke (NINDS), NIH, 9000 Rockville Pike, Bethesda, MD 20892, USA.
ISSN:2372-3556
2372-3556
DOI:10.1080/23723556.2018.1465881